SCHEMBL6328213

SCHEMBL6328213

COC(=O)C=Cc1ccccc1CC1CCC(=O)N(c2c(C)cccc2C)C1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 3/20 0.35
KMT2A Q03164 3/20 0.35
PTGER4 P35408 3/20 0.34
PTGER3 P43115 3/20 0.34
PTGER2 P43116 3/20 0.34
PTGER1 P34995 2/20 0.34
F2 P00734 1/20 0.33
PRSS1 P07477 1/20 0.33
ALDH1A1 P00352 2/20 0.33
HTT P42858 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
PRKDC P78527 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6328210 1.00 P2RX7 (0.35) P2RX7KMT2APTGER4PTGER3PTGER2
SCHEMBL6328576 0.90 MEN1 (0.37) P2RX7KMT2AL3MBTL1MEN1
SCHEMBL6328571 0.90 MEN1 (0.37) P2RX7KMT2AL3MBTL1MEN1
SCHEMBL6329626 0.81 ALDH1A1 (0.44) P2RX7KMT2AALDH1A1HTTL3MBTL1
SCHEMBL6330239 0.78 POLB (0.40) P2RX7KMT2AALDH1A1HTTMEN1
SCHEMBL6328797 0.77 GRIK1 (0.39) P2RX7KMT2AALDH1A1HTT
SCHEMBL6329240 0.76 P2RX7 (0.38) P2RX7KMT2AMEN1
SCHEMBL6328429 0.75 MAOA (0.37) P2RX7ALDH1A1NPC1RAB9AKDM4E
SCHEMBL6328436 0.75 MAOA (0.37) P2RX7ALDH1A1NPC1RAB9AKDM4E
SCHEMBL6335308 0.75 L3MBTL1 (0.42) ALDH1A1L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050085509-A1 Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO. LTD. (JP) 2005-04-21 US claimed
EP-1447401-A1 PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-08-18 EP claimed
US-20050085509-A1 Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO. LTD. (JP) 2005-04-21 US disclosed
EP-1447401-A1 PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085509-A1 Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient MAPKAP1, MAPK1, MAPK8 P2RX7 2638/4885KMT2A 2311/4885PTGER4 2883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.